MolDX: Blood Product Molecular Antigen Typing

Molecular blood product antigen phenotyping is covered for pre-transfusion evaluation when patients are expected to need long-term frequent transfusions, when serologic reactivity prevents exclusion of clinically significant alloantibodies, when typing sera are unavailable, or when serologic typing discrepancies occur. Laboratory-developed tests may be covered if they demonstrate equivalent or superior validity and clinical utility; single-gene tests are generally not reasonable and necessary except in rare documented cases, and all testing must be documented as medically necessary in the patient's record and comply with germline testing policies.

"Molecular phenotyping of blood product antigens is covered as part of pre-transfusion evaluation when long-term, frequent transfusions are anticipated to prevent alloantibody development (e."

Sign up to see full coverage criteria, indications, and limitations.